GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protagenic Therapeutics Inc (NAS:PTIX) » Definitions » Cyclically Adjusted FCF per Share

Protagenic Therapeutics (Protagenic Therapeutics) Cyclically Adjusted FCF per Share : $-17.53 (As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Protagenic Therapeutics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Protagenic Therapeutics's adjusted free cash flow per share for the three months ended in Dec. 2023 was $-0.260. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-17.53 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 88.60% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 71.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Protagenic Therapeutics was 88.60% per year. The lowest was 9.20% per year. And the median was 22.60% per year.

As of today (2024-04-28), Protagenic Therapeutics's current stock price is $1.385. Protagenic Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $-17.53. Protagenic Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Protagenic Therapeutics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Protagenic Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protagenic Therapeutics Cyclically Adjusted FCF per Share Chart

Protagenic Therapeutics Annual Data
Trend Jun14 Jun15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13,192.80 -11,751.60 -11,218.70 -422.69 -17.53

Protagenic Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -422.69 -28.74 -28.36 -20.41 -17.53

Competitive Comparison of Protagenic Therapeutics's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Protagenic Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protagenic Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protagenic Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Protagenic Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Protagenic Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Protagenic Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.26/129.4194*129.4194
=-0.260

Current CPI (Dec. 2023) = 129.4194.

Protagenic Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -16.571 99.695 -21.512
201406 -12.429 100.560 -15.996
201409 -11.429 100.428 -14.728
201412 -15.857 99.070 -20.715
201503 -13.143 99.621 -17.074
201506 -13.571 100.684 -17.444
201509 -14.571 100.392 -18.784
201512 -15.143 99.792 -19.639
201603 -19.000 100.470 -24.475
201606 -0.269 101.688 -0.342
201609 -0.149 101.861 -0.189
201612 -0.133 101.863 -0.169
201703 -0.139 102.862 -0.175
201706 -0.096 103.349 -0.120
201709 -0.140 104.136 -0.174
201712 -0.163 104.011 -0.203
201803 -0.101 105.290 -0.124
201806 -0.135 106.317 -0.164
201809 -0.062 106.507 -0.075
201812 -0.120 105.998 -0.147
201903 -0.076 107.251 -0.092
201906 -0.032 108.070 -0.038
201909 -0.024 108.329 -0.029
201912 -0.058 108.420 -0.069
202003 -0.142 108.902 -0.169
202006 -0.057 108.767 -0.068
202009 -0.202 109.815 -0.238
202012 -0.122 109.897 -0.144
202103 -0.231 111.754 -0.268
202106 -0.196 114.631 -0.221
202109 -0.260 115.734 -0.291
202112 -0.094 117.630 -0.103
202203 -0.100 121.301 -0.107
202206 -0.196 125.017 -0.203
202209 -0.124 125.227 -0.128
202212 -0.042 125.222 -0.043
202303 -0.086 127.348 -0.087
202306 -0.354 128.729 -0.356
202309 -0.151 129.860 -0.150
202312 -0.260 129.419 -0.260

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Protagenic Therapeutics  (NAS:PTIX) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Protagenic Therapeutics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Protagenic Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Protagenic Therapeutics (Protagenic Therapeutics) Business Description

Traded in Other Exchanges
Address
149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
Executives
Alexander K. Arrow officer: Chief Financial Officer PO BOX 3094, REDWOOD CITY CA 94064
Jennifer Buell director 3 FORBES ROAD, LEXINGTON MA 02421
Brian Corvese director C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010
Robert Benjamin Stein director C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421
Khalil Barrage director 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010
Gregory Ekizian director 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010
Robert Ziroyan officer: COO / Interim President 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010
Joshua Silverman director IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Garo H Armen director, 10 percent owner, officer: See Remarks 3 FORBES ROAD, LEXINGTON MA 02421
Edward J Gildea director, officer: Chief Executive Officer C/O CONVERTED ORGANICS INC., 7A COMMERCIAL WHARF WEST, BOSTON MA 02110
David J Horin officer: Chief Financial Officer 1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020
Jonathan Schechter director C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165
Nathan Yu-gai Fong officer: Chief Financial Officer THE ORCHARD ENTERPRISES, INC., 23 E. 4TH ST., 3RD FL., NEW YORK NY 10003
Sharon Siegel officer: Chief Marketing Officer C/O ATRINSIC, INC., 469 SEVENTH AVENUE, 10TH FLOOR, NEW YORK NY 10018
Raymond Musci director, officer: Exec VP, Corporate Development C/O BRILLIANT DIGITAL ENTERTAINMENT INC, 6355 TOPANGA CANYON BOULEVARD SUITE 520, WOODLAND HILLS CA 91367